Summit Therapeutics is focused on the discovery, development and commercialisation of novel medicines for diseases for which there are no existing or only inadequate therapies. Summit is advancing new therapies for the treatment of rare diseases and infectious diseases. Our goal is to become a fully integrated biopharmaceutical company.
Our clinical focus is currently on the rare genetic disease Duchenne muscular dystrophy (‘DMD’) and the infectious disease caused by Clostridium difficile bacteria.
DMD, is one of the most common, fatal genetic disorders diagnosed in children around the world. Estimated to affect approximately 50,000 patients in the developed world, DMD results in the progressive wasting of muscles throughout the body. There is currently no approved disease-modifying therapy for DMD that would treat all patients with the disease. Consequently, life expectancy for DMD patients is in the late twenties. We are developing small molecule utrophin modulators as a potential disease modifying treatment that would be applicable to all patients with this devastating disease. We are applying our leadership position in the field of utrophin modulation to advance our lead DMD drug candidate, ezutromid (formerly SMT C1100), through patient clinical trials and in parallel to develop a pipeline of future generation utrophin modulators.
Clostridium difficile infection, or CDI, is a serious illness and a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. The key clinical issue with CDI is disease recurrence, with each additional episode of CDI being associated with greater disease severity, higher mortality rates and an increased burden on the healthcare system. We are developing ridinilazole (formerly SMT19969), a novel antibiotic designed to selectively target C. difficile that has the potential to treat the initial infection and reduce rates of recurrent disease.
We are seeking to rapidly advance the development of our lead product candidates, ezutromid for DMD and ridinilazole for CDI, through patient clinical trials with the goal of seeking to maximise the commercial opportunity for each of these candidates, including potentially by entering into collaboration arrangements with third parties or by retaining our commercialisation rights. To this end, we have entered into an exclusive licence and collaboration agreement, granting Sarepta Therapeutics European rights to our utrophin modulator pipeline and an exclusive licence and commercialization agreement, granting Eurofarma Laboratorios SA Latin American rights to ridinilazole.
Summit was founded in 2003 as a spin-out of the University of Oxford and our shares are listed on the Alternative Investment Market, or AIM, of the London Stock Exchange (symbol ‘SUMM’) and the NASDAQ Global Market (symbol ‘SMMT’). We are headquartered in Oxfordshire, UK and have offices in Cambridge, Massachusetts, US and Cambridge, UK.